Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.35 |
| ▸ | PTGIR | P43119 | 2/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696892 | 0.91 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL6256094 | 0.91 | — | — | |
| SCHEMBL17029138 | 0.91 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL23675572 | 0.85 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL5682345 | 0.85 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL5680245 | 0.83 | ALDH1A1 (0.34) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL7186641 | 0.83 | LMNA (0.37) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL10020225 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL22856596 | 0.83 | LMNA (0.37) | ALDH1A1LMNAHSD17B10JAK2JAK1 | |
| SCHEMBL3478687 | 0.83 | NLRP3 (0.39) | ALDH1A1LMNAHSD17B10JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721100-B1 | ENVIRONMENTALLY FRIENDLY COALESCING AGENTS | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2020-08-19 | — | — | EP | disclosed |
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADENOSINE THERAPEUTICS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2721100-A1 | ENVIRONMENTALLY FRIENDLY COALESCING AGENTS | Myriant Corporation (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8551972-B2 | Agonists of A2A adenosine receptors for treating recurrent tumor growth | ADENOSINE THERAPEUTICS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | The Regents of the University of Colorado, a body corporation (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2266994-B1 | 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity | Univ Virginia Patent Found (US) | 2013-04-03 | — | — | EP | disclosed |
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2012173679-A1 | ENVIRONMENTALLY FRIENDLY COALESCING AGENTS | MYRIANT CORPORATION (US) | 2012-12-20 | — | — | WO | disclosed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| EP-1205498-A1 | (Meth)acrylate ester-based resin composition | Nippon Shokubai Co., Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-20020045702-A1 | (Meth)acrylate ester-based resin composition | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1194440-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1184396-A1 | (Meth)acrylate ester-based resin composition | Nippon Shokubai Co., Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-6322771-B1 | PARENTERALLY ADMINISTERING TO A MAMMAL A PURINE DERIVATIVE TO DIAGNOSE CORONARY ARTERY STENOSIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-11-27 | — | — | US | disclosed |
| EP-1150991-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-10-04 | — | — | US | disclosed |
| US-6232297-B1 | ADMINISTERING 4-AMINOPYRROLO(3,2-D)PYRIMIDINE DERIVATIVE AS ADENOSINE RECEPTOR ANTAGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2001-05-15 | — | — | US | disclosed |
| WO-2000078774-A2 | INDUCTION OF PHARMACOLOGICAL STRESS WITH ADENOSINE RECEPTOR AGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000044763-A2 | COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | ADORA3, ADORA2A, ADORA2B | ALDH1A1 2031/4885LMNA 2273/4885HSD17B10 4851/4885 |
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | ALDH1A1 659/4885LMNA 4253/4885HSD17B10 3490/4885 |
| US-20010027185-A1 | Methods and compositions for treating inflammatory response | LTB4R2, ADORA2A, PTGES2 | ALDH1A1 1787/4885LMNA 2436/4885HSD17B10 2369/4885 |
| US-20020045702-A1 | (Meth)acrylate ester-based resin composition | MNAT1, MAT1A, COPE | ALDH1A1 298/4885LMNA 1220/4885HSD17B10 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.